文献速递胸部心血管技术与安全CTMRUSPET

COVID-19的心脏和肺部多模态成像

Heart and Lung Multimodality Imaging in COVID-19.
PubMed 文献 · JACC Cardiovasc Imaging · 2020-06-24

本文综述了COVID-19心脏和肺部受累的影像导向病理生理机制,并提供了综合影像评估指南。约40%住院COVID-19患者有心血管疾病史,心肌损伤比例高达12%,心脏受累从亚临床心肌损伤到心肌炎、心肌梗死、肺栓塞和心力衰竭。心脏和肺部多模态成像在诊断、风险分层和管理中起核心作用。

要点

  • 约40%住院COVID-19患者有心血管疾病史
  • COVID-19患者中心肌损伤比例高达12%
  • 心脏和肺部多模态成像在COVID-19患者的诊断、风险分层和管理中起核心作用

核心结论

  • 综合心脏和肺部多模态成像在不同临床环境中起核心作用,对COVID-19患者的诊断、风险分层和管理至关重要。
  • 本综述旨在总结COVID-19肺和心脏受累的影像导向病理生理机制,并为这些患者的综合影像评估提供指南。

研究设计与样本

  • 综述,旨在总结COVID-19肺和心脏受累的影像导向病理生理机制,并为综合影像评估提供指南。
  • 原文未报告检索范围与纳入文献标准。

关键影像表现/征象

  • COVID-19主要临床特征为急性呼吸综合征,从轻度症状性间质性肺炎到急性呼吸窘迫综合征不等。
  • 心脏受累可能从亚临床心肌损伤到明确的临床实体(心肌炎、心肌梗死、肺栓塞和心力衰竭),其发生率和预后意义因影像数据显著缺乏目前 largely 未知。

诊断标准与关键数值

  • 约40%住院COVID-19患者有心血管疾病史。
  • COVID-19患者中心肌损伤比例高达12%。
  • 心脏受累可能从亚临床心肌损伤到明确的临床实体(心肌炎、心肌梗死、肺栓塞和心力衰竭),其发生率和预后意义因影像数据显著缺乏目前 largely 未知。

临床应用与阅片要点

  • 综合心脏和肺部多模态成像在不同临床环境中起核心作用,对COVID-19患者的诊断、风险分层和管理至关重要。
  • 本综述为COVID-19患者的综合影像评估提供指南。

局限性

  • 心肌损伤和心脏受累的发生率和预后意义因影像数据显著缺乏目前 largely 未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The severe acute respiratory syndrome-coronavirus-2 outbreak has rapidly reached pandemic proportions and has become a major threat to global health. Although the predominant clinical feature of coronavirus disease-2019 (COVID-19) is an acute respiratory syndrome of varying severity, ranging from mild symptomatic interstitial pneumonia to acute respiratory distress syndrome, the cardiovascular system can be involved in several ways. As many as 40% of patients hospitalized with COVID-19 have histories of cardiovascular disease, and current estimates report a proportion of myocardial injury in patients with COVID-19 of up to 12%. Multiple pathways have been suggested to explain this finding and the related clinical scenarios, encompassing local and systemic inflammatory responses and oxygen supply-demand imbalance. From a clinical point of view, cardiac involvement during COVID-19 may present a wide spectrum of severity, ranging from subclinical myocardial injury to well-defined clinical entities (myocarditis, myocardial infarction, pulmonary embolism, and heart failure), whose incidence and prognostic implications are currently largely unknown because of a significant lack of imaging data. Integrated heart and lung multimodality imaging plays a central role in different clinical settings and is essential in the diagnosis, risk stratification, and management of patients with COVID-19. The aims of this review are to summarize imaging-oriented pathophysiological mechanisms of lung and cardiac involvement in COVID-19 and to provide a guide for integrated imaging assessment in these patients.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Agricola E, Beneduce A, Esposito A, et al. Heart and Lung Multimodality Imaging in COVID-19. JACC Cardiovasc Imaging. 2020. PMID: 32762885. doi:10.1016/j.jcmg.2020.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。